BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 17667528)

  • 1. Manufacturing of large numbers of patient-specific T cells for adoptive immunotherapy: an approach to improving product safety, composition, and production capacity.
    Tran CA; Burton L; Russom D; Wagner JR; Jensen MC; Forman SJ; DiGiusto DL
    J Immunother; 2007 Sep; 30(6):644-54. PubMed ID: 17667528
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A sealed and unbreached system for purification, stimulation, and expansion of cytomegalovirus-specific human CD4 and CD8 T lymphocytes.
    Li Pira G; Bottone L; Ivaldi F; Pelizzoli R; Risso M; Tripodi G; Manca F
    Transfusion; 2006 Dec; 46(12):2053-62. PubMed ID: 17176316
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Manufacturing of gene-modified cytotoxic T lymphocytes for autologous cellular therapy for lymphoma.
    Cooper LJ; Ausubel L; Gutierrez M; Stephan S; Shakeley R; Olivares S; Serrano LM; Burton L; Jensen MC; Forman SJ; DiGiusto DL
    Cytotherapy; 2006; 8(2):105-17. PubMed ID: 16698684
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Positive selection and expansion of cytomegalovirus-specific CD4 and CD8 T cells in sealed systems: potential applications for adoptive cellular immunoreconstitution.
    Li Pira G; Ivaldi F; Tripodi G; Martinengo M; Manca F
    J Immunother; 2008 Oct; 31(8):762-70. PubMed ID: 18779743
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Generation of EBV-specific T cells for adoptive immunotherapy: a novel protocol using formalin-fixed stimulator cells to increase biosafety.
    Hammer MH; Brestrich G; Mittenzweig A; Roemhild A; Zwinger S; Subklewe M; Beier C; Kurtz A; Babel N; Volk HD; Reinke P
    J Immunother; 2007; 30(8):817-24. PubMed ID: 18049333
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical grade generation of hexon-specific T cells for adoptive T-cell transfer as a treatment of adenovirus infection after allogeneic stem cell transplantation.
    Feuchtinger T; Richard C; Joachim S; Scheible MH; Schumm M; Hamprecht K; Martin D; Jahn G; Handgretinger R; Lang P
    J Immunother; 2008; 31(2):199-206. PubMed ID: 18481389
    [TBL] [Abstract][Full Text] [Related]  

  • 7. GMP production and testing of Xcellerated T Cells for the treatment of patients with CLL.
    Hami LS; Green C; Leshinsky N; Markham E; Miller K; Craig S
    Cytotherapy; 2004; 6(6):554-62. PubMed ID: 15764021
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tetanus toxoid provides efficient T-cell help for the induction of HA-1(H) cytotoxic T cells.
    Eiz-Vesper B; Horn PA; Daubert C; Khattab B; Blasczyk R
    Transfusion; 2006 Jul; 46(7):1210-20. PubMed ID: 16836569
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ex vivo expansion of the highly cytotoxic human natural killer-92 cell-line under current good manufacturing practice conditions for clinical adoptive cellular immunotherapy.
    Tam YK; Martinson JA; Doligosa K; Klingemann HG
    Cytotherapy; 2003; 5(3):259-72. PubMed ID: 12850795
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of an automated closed fluid management device for processing expanded cytokine-induced killer cells to use in immunotherapy programs for cancer.
    Giancola R; Olioso P; Di Riti M; Capone A; Contento A; Pompetti F; Iacone A
    Transfusion; 2008 Apr; 48(4):629-39. PubMed ID: 18208417
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Purification of melanoma reactive T cell by using a monocyte-based solid phase T-cell selection system for adoptive therapy.
    Li J; Mookerjee B; Wagner J
    J Immunother; 2008 Jan; 31(1):81-8. PubMed ID: 18157015
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Large-scale expansion of cytomegalovirus-specific cytotoxic T cells in suspension culture.
    Foster AE; Forrester K; Gottlieb DJ; Barton GW; Romagnoli JA; Bradstock KF
    Biotechnol Bioeng; 2004 Jan; 85(2):138-46. PubMed ID: 14704996
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Scalable expansion of potent genetically modified human langerhans cells in a closed system for clinical applications.
    Yuan J; Kendle R; Ireland J; Heller G; Sadelain M; Young JW; Rivière I
    J Immunother; 2007 Sep; 30(6):634-43. PubMed ID: 17667527
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical-scale single-step CD4(+) and CD8(+) cell depletion for donor innate lymphocyte infusion (DILI).
    Smetak M; Kimmel B; Birkmann J; Schaefer-Eckart K; Einsele H; Wilhelm M; Kunzmann V
    Bone Marrow Transplant; 2008 Apr; 41(7):643-50. PubMed ID: 18037935
    [TBL] [Abstract][Full Text] [Related]  

  • 15. GMP production of anti-tumor cytotoxic T-cell lines for adoptive T-cell therapy in patients with solid neoplasia.
    Turin I; Pedrazzoli P; Tullio C; Montini E; La Grotteria MC; Schiavo R; Perotti C; Locatelli F; Carretto E; Maccario R; Siena S; Montagna D
    Cytotherapy; 2007; 9(5):499-507. PubMed ID: 17786611
    [TBL] [Abstract][Full Text] [Related]  

  • 16. T-cell reconstitution and expansion after hematopoietic stem cell transplantation: 'T' it up!
    Porter DL; June CH
    Bone Marrow Transplant; 2005 May; 35(10):935-42. PubMed ID: 15806121
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Modifying interleukin-2 concentrations during culture improves function of T cells for adoptive immunotherapy.
    Besser MJ; Schallmach E; Oved K; Treves AJ; Markel G; Reiter Y; Schachter J
    Cytotherapy; 2009; 11(2):206-17. PubMed ID: 19148842
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Detailed analysis of IFNg response upon activation permits efficient isolation of cytomegalovirus-specific CD8+ T cells for adoptive immunotherapy.
    Zandvliet ML; Falkenburg JH; Jedema I; Willemze R; Guchelaar HJ; Meij P
    J Immunother; 2009 Jun; 32(5):513-23. PubMed ID: 19609244
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Human purified CD8+ T cells: Ex vivo expansion model to generate a maximum yield of functional cytotoxic cells.
    Al-Shanti N; Aldahoudi Z
    Immunol Invest; 2007; 36(1):85-104. PubMed ID: 17190652
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Large scale expansion of gamma 9 delta 2 T lymphocytes: Innacell gamma delta cell therapy product.
    Salot S; Laplace C; Saïagh S; Bercegeay S; Tenaud I; Cassidanius A; Romagne F; Dreno B; Tiollier J
    J Immunol Methods; 2007 Sep; 326(1-2):63-75. PubMed ID: 17716681
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.